Why Moderna (MRNA) Stock Is Falling Today
Update: 2025-11-03
Description
Moderna's foray into cancer research with a new multiple myeloma therapy fails to impress Wall Street, as the company grapples with a significant drop in revenue and a grim financial outlook. Recent vaccine pipeline setbacks further dampen hopes for a comeback, despite the positive news from the cancer therapy trial. Moderna's stock has been on a rollercoaster ride, with shares down over forty percent this year, leaving long-term investors with less than half of their initial investment. The market remains skeptical, awaiting concrete results to determine if Moderna's new research direction can truly turn the tide.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
